Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro SA announcing that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium. It details the legal status of the company, the appointment of a commissary, and the postponement of its half-year financial results. Since this is a regulatory announcement regarding the company's financial and legal status that does not fit into specific categories like M&A or dividend notices, it is classified as a Regulatory Filing (RNS).
2024-09-30 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro SA announcing the initiation of a 'sursis concordataire' (a Swiss legal procedure for debt restructuring/preventive bankruptcy protection). It details the court's decision, the appointment of a commissioner, and the impact on the company's operations and financial reporting schedule. This falls under the category of significant corporate events related to financial distress and legal restructuring, which is best classified as a Regulatory Filing (RNS) as it does not fit into specific categories like M&A or share issues, and it is not a financial report itself.
2024-09-30 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the presentation of new scientific data regarding their drug candidate, Temelimab, at the ECTRIMS 2024 Congress. It describes clinical research findings and the company's ongoing mission. As this is a general corporate announcement regarding research and development progress that does not fit into specific financial reporting categories like 10-K, IR, or ER, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2024-09-19 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the presentation of new scientific data regarding their drug candidate, Temelimab, at the ECTRIMS 2025 congress. It details research findings, the mechanism of action, and quotes from the CEO. It does not fit into financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding research and development progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2024-09-19 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing that it has filed for a 'sursis concordataire' (a Swiss legal procedure for debt restructuring/preventative bankruptcy protection) following unsuccessful clinical trial results. This document details a significant change in the company's financial and operational status, specifically regarding debt restructuring and potential insolvency proceedings. It does not fit into standard financial reporting categories like 10-K or IR, nor is it a simple report announcement. Given the nature of the announcement regarding debt and corporate restructuring, it falls under the 'Regulatory Filings' (RNS) category as a material corporate event announcement.
2024-07-15 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the termination of a liquidity contract with Gilbert Dupont. It details the final balance of shares and cash held in the liquidity account at the time of termination. This type of announcement regarding the status of share-related contracts and treasury management falls under the category of regulatory announcements concerning share capital and market operations, which is best classified as a Regulatory Filing (RNS) as it does not fit into specific categories like 'Transaction in Own Shares' (which usually refers to buybacks) or 'Share Issue'.
2024-07-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.